Micron Technology (MU) announced that its board of directors have approved a quarterly dividend of $0.10 per share. Shares of the semiconductor company rallied 1.2% to close at $78.59 in the extended trading session on Monday.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The initial dividend will be paid on October 18, 2021, to shareholders of record as of October 1, 2021.
Notably, the company also has a share repurchase plan of up to $10 billion in place. The repurchases can be made through open-market purchases, block trades, privately negotiated transactions, derivative transactions, and/or pursuant to Rule 10b5-1 trading plans. (See Micron stock chart on TipRanks)
The President and CEO of Micron Technology, Sanjay Mehrotra, said, “Initiating a common stock dividend reflects our confidence in Micron’s future and our commitment to creating compelling value for shareholders.”
On June 30, Micron reported Fiscal Year 2021 third-quarter results, which witnessed substantial improvement from the prior-year quarter and topped consensus estimates.
On August 2, Rosenblatt Securities analyst Hans Mosesmann reiterated a Buy rating on the stock. Mosesmann is of the opinion that Micron’s memory/storage content/bandwidth is accelerating due to AI-related workloads that are not keeping up with the computing engines.
He said, “Micron is changing its share repurchase tactics to be cross-cyclical than yearly, to opportunistically be aggressive when shares are below their intrinsic value; as management believes is the case for the current August quarter.”
Based on 17 Buys and 5 Holds, the stock has a Strong Buy consensus. The average Micron price target of $116 implies 49.4% upside potential. Shares have gained 54.1% over the past year.
Related News:
Scotts Miracle-Gro Rewards Shareholders with 6.5% Dividend Hike; Street Says Buy
W.P. Carey Q2 Results Top Estimates; Street Says Buy
FDA Approves Johnson & Johnson IV Drug
